{"success":true,"data":{"pressRelease":{"id":"121206","rtpr_id":"nPn2Vx814a","ticker":"2269","exchange":"HKEX","all_tickers":["2269"],"title":"WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO","author":"PR Newswire","published_at":"2026-08-18T07:04:59.030Z","article_body":"WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO\n\nPR Newswire\n\nSHANGHAI, Aug. 18, 2026\n\nSHANGHAI, Aug. 18, 2026 /PRNewswire/ -- BioPharma APAC recently published its\nTop 26 - Companies Leading Sustainable Biopharma Practices in 2026,\nhighlighting leading sustainability practices across pharmaceutical companies,\nbiotechnology firms and CRDMOs in Europe, North America and Asia Pacific, with\na focus on Science Based Targets initiative (SBTi) commitments, value-chain\ndecarbonization, green manufacturing, and sustainable operations. The list\nbrings together global pharmaceutical leaders – such as MSD (Merck &\nCo.), Eli Lilly, Johnson & Johnson, AstraZeneca, Takeda, GSK and Bayer –\ncollectively illustrating the diverse pathways through which players across\nthe industry value chain are advancing the green transition, with WuXi\nBiologics was featured for its outstanding sustainability practices,\nreflecting international industry recognition of the Company's empowering\ncontributions through green CRDMO.\n\nSustainability is evolving from a corporate social responsibility requirement\ninto an important driver of industry advancement and corporate\ncompetitiveness. For the biopharmaceutical industry, climate change, resource\nefficiency and supply-chain governance have become core areas of focus. More\ncompanies are seeking the best ways to answer a critical question: how can\nthey pursue innovation and business growth while advancing a greener,\nlower-carbon and more sustainable development model?\n\nAt WuXi Biologics, Green CRDMO is Sustainability in action\n\nThe Company's Green CRDMO solution turns sustainability into an integrated\ncapability that is practical, measurable and empowering, connecting\nsustainability progress with productivity, operational resilience and\nlong-term competitiveness to create tangible and sustainable value for global\nclients.\n\nAcross the global healthcare and biopharmaceutical value chain, sustainability\nis becoming a strategic priority for creating business value. Companies are\nexpected to set science-based climate targets and net-zero commitments, reduce\nScope 3 value-chain carbon emissions, quantify product carbon footprints,\nrespond to global green procurement requirements, and disclose environmental\nperformance with greater transparency. Green CRDMO solution is therefore not\nan add-on to traditional services, but a bridge that translates governance\npractices into business value by helping clients enhance corporate governance,\nreduce operating costs, capture green-financing opportunities, establish\nproduct-level carbon transparency, strengthen competitiveness in government\nprocurement that emphasizes ESG performance, and improve overall supply-chain\nresilience.\n\nIn Green Research, WuXi Biologics starts with \"For Patients. For Planet.\" The\nCompany leverages its integrated end-to-end CRDMO platform and innovative\ntechnologies to shorten the journey from molecule to patient. Discovery\nplatforms such as WuXiBody™ accelerate the development of antibodies and\ncomplex molecules, improve developability and stability, and enable innovative\ntherapies to reach patients faster, at greater scale and with higher quality.\nBy simplifying bispecific antibody development and shortening R&D\ntimelines by 6–18 months, WuXiBody™ improves R&D efficiency while\nreducing the natural resources and energy required to maintain research\nenvironments.\n\nIn Green Development, WuXi Biologics uses advanced platforms including\nWuXia™, WuXiUP™ and WuXiUI™ to improve productivity, reduce resource use\nand provide more efficient and flexible process pathways for innovative\nbiologics. The WuXia™ TrueSite cell line development platform further\nimproves development efficiency and quality through technological innovation,\nachieving monoclonal antibody titers of 8–12 g/L — supporting high-yield\ncommercial manufacturing requirements — and shortening to approximately\nsix-month timeline from DNA to IND filing readiness. The WuXiUI™\nultra-intensified fed-batch platform boosts productivity by 3 to 8 times and\nreduces lifecycle environmental impacts by up to 60% compared with traditional\nfed-batch processes, making development lower-carbon, more efficient and more\nsustainable, while improving capacity, quality consistency and operational\nagility.\n\nIn Green Manufacturing, WuXi Biologics leverages single-use technology (SUT)\nand process innovation to scale green manufacturing. Compared with traditional\nstainless-steel processes, SUT can save up to 70% of water, reduce resource\nuse by approximately 33%, and lower negative climate-change impacts by\napproximately 40%. (End-of-life treatment accounts for only 1%–3% of its\nlifecycle environmental impact and is therefore negligible.) In addition, the\nCompany remains committed to responsible waste management through zero waste\nto landfill, waste-to-energy utilization, continued reduction of SUT waste,\nand exploration of more environmentally friendly SUT recycling solutions.\nCombining WuXiUI™ with SUT can reduce the product carbon footprint per gram\nof protein by up to 80%, providing clients with manufacturing solutions that\ndeliver both environmental and operational benefits. WuXi Biologics also uses\nlifecycle assessment (LCA) modeling and calculation capabilities to support\nits cradle-to-gate product carbon-footprint measurements and enable\nproduct-level carbon transparency. Clearer, traceable carbon data helps\nclients make better low-carbon decisions, manage Scope 3 emissions, and\nadvance value-chain decarbonization.\n\nIn Green Operations, WuXi Biologics embeds sustainability across its global\noperations, and uses lean management and digital tools to improve resource and\nenergy efficiency, delivering further reductions in carbon emissions, water\nuse and waste. Its Green CRDMO solution was selected as a United Nations\nGlobal Compact \"20 Cases for 20 Years\" corporate sustainability case. The WuXi\nBiologics Green CRDMO White Paper systematically shares practices across green\nresearch, development, manufacturing and operations, outlining 242\nenergy-saving cases covering 12 major energy systems and five key\nenergy-saving scenarios across 25 categories of energy-saving technologies,\nand supporting the replication of green operational practices across global\nsites and the industry value chain.\n\nClimate action remains a central pillar of the Company's Green CRDMO strategy.\nWuXi Biologics has obtained SBTi validation for its near-term, long-term and\nnet-zero targets, and has committed to achieving net-zero emissions across its\nvalue chain by 2050. To support these ambitions, the Company continues to\nadvance energy efficiency initiatives, renewable energy adoption, green\noperations, and supply-chain collaboration. BioPharma APAC specifically\nhighlighted WuXi Biologics' SBTi-approved targets and commitment to\nsustainable transformation within the biopharmaceutical industry.\n\nIn recent years, WuXi Biologics has continued to receive international\nrecognition for its sustainability performance, including the highest MSCI AAA\nESG rating; the EcoVadis Platinum Medal, placing the Company in the global top\n1%; inclusion in the Dow Jones Best-in-Class World Index and Dow Jones\nBest-in-Class Emerging Markets Index; CDP \"A List\" recognition for Climate\nChange, Water Security and Supplier Engagement Assessment; the highest\n\"Negligible Risk\" rating from Morningstar Sustainalytics and recognition as an\nESG Industry and Regional ESG Leader; inclusion in the FTSE4Good Index Series;\nthe ISS ESG Prime status; and inclusion in the Hang Seng Corporate\nSustainability Benchmark Index. These recognitions underscore the Company's\nprogress across environmental, social and governance areas, as well as global\nstakeholder recognition of its sustainability strategy and performance.\n\nGreen manufacturing is not only an important sustainability commitment, but\nalso a key pathway to enhancing competitiveness, productivity and operational\nresilience.\n\nAs a global leader in green biologics solutions, WuXi Biologics will continue\nto advance green technology innovation and create shared sustainable value for\nglobal partners through its end-to-end Green CRDMO solution, working with\nstakeholders across the value chain toward a greener and healthier future.\n\nAbout WuXi Biologics\n\nWuXi Biologics (stock code: 2269.HK) is a leading global Contract Research,\nDevelopment and Manufacturing Organization (CRDMO) offering end-to-end\nsolutions that enable partners to discover, develop and manufacture biologics\n— from concept to commercialization — for the benefit of patients\nworldwide*.\n\nWith over 13,000 employees in China, the United States, Ireland, Germany, and\nSingapore — including experts and scientists in biologics R&D and\nmanufacturing, technology innovation, and operational excellence — WuXi\nBiologics leverages its technologies and expertise to deliver efficient,\ncost-effective, and scalable biologics solutions tailored to meet\nclients'needs. By embedding digital capability and infrastructure across the\nfull biopharmaceutical value chain, the company turns data, computation, and\nprediction into transparent client experience, faster development, intelligent\noperations, and more efficient manufacturing. As of April 30, 2026, WuXi\nBiologics is supporting 982 integrated client projects, including 78 in Phase\nIII and 25 in commercial manufacturing, with complex modalities representing\nmore than half of the entire project portfolio.\n\nWuXi Biologics regards sustainability as the cornerstone of long-term business\ngrowth. The company continuously drives technology innovations to offer\nadvanced end-to-end Green CRDMO solutions for its global partners while\ndemonstrating exemplary Environmental, Social and Governance (ESG) practices.\nCommitted to creating shared value, it collaborates with all stakeholders to\nfoster positive social and environmental impacts, and promote responsible\npractices that empower the entire value chain.\n\nFor more information about WuXi Biologics, please visit: www.wuxibiologics.com\n(https://www.wuxibiologics.com/) .\n\n*The winner of the \"2026 Biologics CDMO of the Year\" (Large CDMOs) (Life\nScience Connect / Outsourced Pharma)\n*The winner of the \"2026 Best Contract Development & Manufacturing\nOrganization Award\" (ABEA)\n\nWuXi Biologics Contacts\nESG\nesg@wuxibiologics.com (mailto:esg@wuxibiologics.com)\nMedia\nPR@wuxibiologics.com (mailto:PR@wuxibiologics.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/wuxi-biologics-recognized-for-industry-top-sustainable-biopharma-practices-empowering-the-industrys-transformation-through-green-crdmo-302853794.html\n(https://www.prnewswire.com/news-releases/wuxi-biologics-recognized-for-industry-top-sustainable-biopharma-practices-empowering-the-industrys-transformation-through-green-crdmo-302853794.html)\n\nSOURCE WuXi Biologics\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2Vx814a","title":"WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO","author":"PR Newswire","ticker":"2269","created":"2026-08-18T07:04:59.030Z","tickers":["2269"],"exchange":"HKEX","article_body":"WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO\n\nPR Newswire\n\nSHANGHAI, Aug. 18, 2026\n\nSHANGHAI, Aug. 18, 2026 /PRNewswire/ -- BioPharma APAC recently published its\nTop 26 - Companies Leading Sustainable Biopharma Practices in 2026,\nhighlighting leading sustainability practices across pharmaceutical companies,\nbiotechnology firms and CRDMOs in Europe, North America and Asia Pacific, with\na focus on Science Based Targets initiative (SBTi) commitments, value-chain\ndecarbonization, green manufacturing, and sustainable operations. The list\nbrings together global pharmaceutical leaders – such as MSD (Merck &\nCo.), Eli Lilly, Johnson & Johnson, AstraZeneca, Takeda, GSK and Bayer –\ncollectively illustrating the diverse pathways through which players across\nthe industry value chain are advancing the green transition, with WuXi\nBiologics was featured for its outstanding sustainability practices,\nreflecting international industry recognition of the Company's empowering\ncontributions through green CRDMO.\n\nSustainability is evolving from a corporate social responsibility requirement\ninto an important driver of industry advancement and corporate\ncompetitiveness. For the biopharmaceutical industry, climate change, resource\nefficiency and supply-chain governance have become core areas of focus. More\ncompanies are seeking the best ways to answer a critical question: how can\nthey pursue innovation and business growth while advancing a greener,\nlower-carbon and more sustainable development model?\n\nAt WuXi Biologics, Green CRDMO is Sustainability in action\n\nThe Company's Green CRDMO solution turns sustainability into an integrated\ncapability that is practical, measurable and empowering, connecting\nsustainability progress with productivity, operational resilience and\nlong-term competitiveness to create tangible and sustainable value for global\nclients.\n\nAcross the global healthcare and biopharmaceutical value chain, sustainability\nis becoming a strategic priority for creating business value. Companies are\nexpected to set science-based climate targets and net-zero commitments, reduce\nScope 3 value-chain carbon emissions, quantify product carbon footprints,\nrespond to global green procurement requirements, and disclose environmental\nperformance with greater transparency. Green CRDMO solution is therefore not\nan add-on to traditional services, but a bridge that translates governance\npractices into business value by helping clients enhance corporate governance,\nreduce operating costs, capture green-financing opportunities, establish\nproduct-level carbon transparency, strengthen competitiveness in government\nprocurement that emphasizes ESG performance, and improve overall supply-chain\nresilience.\n\nIn Green Research, WuXi Biologics starts with \"For Patients. For Planet.\" The\nCompany leverages its integrated end-to-end CRDMO platform and innovative\ntechnologies to shorten the journey from molecule to patient. Discovery\nplatforms such as WuXiBody™ accelerate the development of antibodies and\ncomplex molecules, improve developability and stability, and enable innovative\ntherapies to reach patients faster, at greater scale and with higher quality.\nBy simplifying bispecific antibody development and shortening R&D\ntimelines by 6–18 months, WuXiBody™ improves R&D efficiency while\nreducing the natural resources and energy required to maintain research\nenvironments.\n\nIn Green Development, WuXi Biologics uses advanced platforms including\nWuXia™, WuXiUP™ and WuXiUI™ to improve productivity, reduce resource use\nand provide more efficient and flexible process pathways for innovative\nbiologics. The WuXia™ TrueSite cell line development platform further\nimproves development efficiency and quality through technological innovation,\nachieving monoclonal antibody titers of 8–12 g/L — supporting high-yield\ncommercial manufacturing requirements — and shortening to approximately\nsix-month timeline from DNA to IND filing readiness. The WuXiUI™\nultra-intensified fed-batch platform boosts productivity by 3 to 8 times and\nreduces lifecycle environmental impacts by up to 60% compared with traditional\nfed-batch processes, making development lower-carbon, more efficient and more\nsustainable, while improving capacity, quality consistency and operational\nagility.\n\nIn Green Manufacturing, WuXi Biologics leverages single-use technology (SUT)\nand process innovation to scale green manufacturing. Compared with traditional\nstainless-steel processes, SUT can save up to 70% of water, reduce resource\nuse by approximately 33%, and lower negative climate-change impacts by\napproximately 40%. (End-of-life treatment accounts for only 1%–3% of its\nlifecycle environmental impact and is therefore negligible.) In addition, the\nCompany remains committed to responsible waste management through zero waste\nto landfill, waste-to-energy utilization, continued reduction of SUT waste,\nand exploration of more environmentally friendly SUT recycling solutions.\nCombining WuXiUI™ with SUT can reduce the product carbon footprint per gram\nof protein by up to 80%, providing clients with manufacturing solutions that\ndeliver both environmental and operational benefits. WuXi Biologics also uses\nlifecycle assessment (LCA) modeling and calculation capabilities to support\nits cradle-to-gate product carbon-footprint measurements and enable\nproduct-level carbon transparency. Clearer, traceable carbon data helps\nclients make better low-carbon decisions, manage Scope 3 emissions, and\nadvance value-chain decarbonization.\n\nIn Green Operations, WuXi Biologics embeds sustainability across its global\noperations, and uses lean management and digital tools to improve resource and\nenergy efficiency, delivering further reductions in carbon emissions, water\nuse and waste. Its Green CRDMO solution was selected as a United Nations\nGlobal Compact \"20 Cases for 20 Years\" corporate sustainability case. The WuXi\nBiologics Green CRDMO White Paper systematically shares practices across green\nresearch, development, manufacturing and operations, outlining 242\nenergy-saving cases covering 12 major energy systems and five key\nenergy-saving scenarios across 25 categories of energy-saving technologies,\nand supporting the replication of green operational practices across global\nsites and the industry value chain.\n\nClimate action remains a central pillar of the Company's Green CRDMO strategy.\nWuXi Biologics has obtained SBTi validation for its near-term, long-term and\nnet-zero targets, and has committed to achieving net-zero emissions across its\nvalue chain by 2050. To support these ambitions, the Company continues to\nadvance energy efficiency initiatives, renewable energy adoption, green\noperations, and supply-chain collaboration. BioPharma APAC specifically\nhighlighted WuXi Biologics' SBTi-approved targets and commitment to\nsustainable transformation within the biopharmaceutical industry.\n\nIn recent years, WuXi Biologics has continued to receive international\nrecognition for its sustainability performance, including the highest MSCI AAA\nESG rating; the EcoVadis Platinum Medal, placing the Company in the global top\n1%; inclusion in the Dow Jones Best-in-Class World Index and Dow Jones\nBest-in-Class Emerging Markets Index; CDP \"A List\" recognition for Climate\nChange, Water Security and Supplier Engagement Assessment; the highest\n\"Negligible Risk\" rating from Morningstar Sustainalytics and recognition as an\nESG Industry and Regional ESG Leader; inclusion in the FTSE4Good Index Series;\nthe ISS ESG Prime status; and inclusion in the Hang Seng Corporate\nSustainability Benchmark Index. These recognitions underscore the Company's\nprogress across environmental, social and governance areas, as well as global\nstakeholder recognition of its sustainability strategy and performance.\n\nGreen manufacturing is not only an important sustainability commitment, but\nalso a key pathway to enhancing competitiveness, productivity and operational\nresilience.\n\nAs a global leader in green biologics solutions, WuXi Biologics will continue\nto advance green technology innovation and create shared sustainable value for\nglobal partners through its end-to-end Green CRDMO solution, working with\nstakeholders across the value chain toward a greener and healthier future.\n\nAbout WuXi Biologics\n\nWuXi Biologics (stock code: 2269.HK) is a leading global Contract Research,\nDevelopment and Manufacturing Organization (CRDMO) offering end-to-end\nsolutions that enable partners to discover, develop and manufacture biologics\n— from concept to commercialization — for the benefit of patients\nworldwide*.\n\nWith over 13,000 employees in China, the United States, Ireland, Germany, and\nSingapore — including experts and scientists in biologics R&D and\nmanufacturing, technology innovation, and operational excellence — WuXi\nBiologics leverages its technologies and expertise to deliver efficient,\ncost-effective, and scalable biologics solutions tailored to meet\nclients'needs. By embedding digital capability and infrastructure across the\nfull biopharmaceutical value chain, the company turns data, computation, and\nprediction into transparent client experience, faster development, intelligent\noperations, and more efficient manufacturing. As of April 30, 2026, WuXi\nBiologics is supporting 982 integrated client projects, including 78 in Phase\nIII and 25 in commercial manufacturing, with complex modalities representing\nmore than half of the entire project portfolio.\n\nWuXi Biologics regards sustainability as the cornerstone of long-term business\ngrowth. The company continuously drives technology innovations to offer\nadvanced end-to-end Green CRDMO solutions for its global partners while\ndemonstrating exemplary Environmental, Social and Governance (ESG) practices.\nCommitted to creating shared value, it collaborates with all stakeholders to\nfoster positive social and environmental impacts, and promote responsible\npractices that empower the entire value chain.\n\nFor more information about WuXi Biologics, please visit: www.wuxibiologics.com\n(https://www.wuxibiologics.com/) .\n\n*The winner of the \"2026 Biologics CDMO of the Year\" (Large CDMOs) (Life\nScience Connect / Outsourced Pharma)\n*The winner of the \"2026 Best Contract Development & Manufacturing\nOrganization Award\" (ABEA)\n\nWuXi Biologics Contacts\nESG\nesg@wuxibiologics.com (mailto:esg@wuxibiologics.com)\nMedia\nPR@wuxibiologics.com (mailto:PR@wuxibiologics.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/wuxi-biologics-recognized-for-industry-top-sustainable-biopharma-practices-empowering-the-industrys-transformation-through-green-crdmo-302853794.html\n(https://www.prnewswire.com/news-releases/wuxi-biologics-recognized-for-industry-top-sustainable-biopharma-practices-empowering-the-industrys-transformation-through-green-crdmo-302853794.html)\n\nSOURCE WuXi Biologics\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-18T07:04:59.090323146Z","server_sent_at_ms":1787036699090},"received_at":"2026-08-18T07:04:59.142Z","source_url":"https://www.prnewswire.com/news-releases/wuxi-biologics-recognized-for-industry-top-sustainable-biopharma-practices-empowering-the-industrys-transformation-through-green-crdmo-302853794.html"},"analysis":{"id":"110193","press_release_id":"121206","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"WuXi Biologics was featured in BioPharma APAC's 'Top 26 - Companies Leading Sustainable Biopharma Practices in 2026,' recognizing its Green CRDMO strategy alongside industry leaders like MSD and Eli Lilly.\n\nThe company highlighted specific operational efficiencies from its platforms, including a 6-18 month reduction in R&D timelines via WuXiBody and up to 70% water savings through single-use technologies compared to stainless-steel processes.\n\nWuXi Biologics confirmed its net-zero target by 2050 and noted it currently supports 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"ESG recognition reinforces brand but lacks material operational trigger."},"keyFigures":{"customDimensions":{"employees":"over 13,000","phase_iii_projects":78,"commercial_projects":25,"energy_saving_cases":242,"sut_water_savings_pct":"up to 70","productivity_boost_times":"3 to 8","dna_to_ind_timeline_months":"approx six","integrated_client_projects":982,"rd_timeline_reduction_months":"6–18","monoclonal_antibody_titers_gl":"8–12","carbon_footprint_reduction_pct":"up to 80","sut_resource_use_reduction_pct":"approx 33","sut_climate_impact_reduction_pct":"approx 40","lifecycle_environmental_impact_reduction_pct":"up to 60"}},"quotedText":"WuXi Biologics has obtained SBTi validation for its near-term, long-term and net-zero targets, and has committed to achieving net-zero emissions across its value chain by 2050.","namedEntities":{"people":[],"products":["WuXiBody™","WuXia™","WuXiUP™","WuXiUI™","Green CRDMO"],"companies":[{"name":"WuXi Biologics","ticker":"2269"},{"name":"MSD (Merck & Co.)","relationship":"competitor"},{"name":"Eli Lilly","relationship":"competitor"},{"name":"Johnson & Johnson","relationship":"competitor"},{"name":"AstraZeneca","relationship":"competitor"},{"name":"Takeda","relationship":"competitor"},{"name":"GSK","relationship":"competitor"},{"name":"Bayer","relationship":"competitor"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Non-financial PR release announcing inclusion in a third-party sustainability list. While it highlights operational efficiency metrics and ESG leadership, it lacks immediate financial impact or material business developments."},"tickerRelevance":{"others":[],"primary":"2269"},"globalImportance":15,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid_large_cap_hk","eventGravity":"esg_recognition","sectorWeight":"health_care"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":1,"narrative":"WuXi Biologics was featured in BioPharma APAC's 'Top 26 - Companies Leading Sustainable Biopharma Practices in 2026,' recognizing its Green CRDMO strategy alongside industry leaders like MSD and Eli Lilly.\n\nThe company highlighted specific operational efficiencies from its platforms, including a 6-18 month reduction in R&D timelines via WuXiBody and up to 70% water savings through single-use technologies compared to stainless-steel processes.\n\nWuXi Biologics confirmed its net-zero target by 2050 and noted it currently supports 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing.","key_figures":{"customDimensions":{"employees":"over 13,000","phase_iii_projects":78,"commercial_projects":25,"energy_saving_cases":242,"sut_water_savings_pct":"up to 70","productivity_boost_times":"3 to 8","dna_to_ind_timeline_months":"approx six","integrated_client_projects":982,"rd_timeline_reduction_months":"6–18","monoclonal_antibody_titers_gl":"8–12","carbon_footprint_reduction_pct":"up to 80","sut_resource_use_reduction_pct":"approx 33","sut_climate_impact_reduction_pct":"approx 40","lifecycle_environmental_impact_reduction_pct":"up to 60"}},"named_entities":{"people":[],"products":["WuXiBody™","WuXia™","WuXiUP™","WuXiUI™","Green CRDMO"],"companies":[{"name":"WuXi Biologics","ticker":"2269"},{"name":"MSD (Merck & Co.)","relationship":"competitor"},{"name":"Eli Lilly","relationship":"competitor"},{"name":"Johnson & Johnson","relationship":"competitor"},{"name":"AstraZeneca","relationship":"competitor"},{"name":"Takeda","relationship":"competitor"},{"name":"GSK","relationship":"competitor"},{"name":"Bayer","relationship":"competitor"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-18T07:08:38.499Z","global_importance":15,"audience_relevance":35,"importance_components":{"tickerTier":"mid_large_cap_hk","eventGravity":"esg_recognition","sectorWeight":"health_care"}},"durationMs":219343,"modelName":"glm-4.7"}}